Document is current
Any future updates will be listed below
-
Authors
Kim, Ho Cheol
Guthrie, Sydney
King, Christopher S.
Khan, Shazia
Thomas, Christopher A.
Khangoora, Vikramjit
Nathan, Steven D.
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 17 June 2025
First Online: 2 July 2025
Declarations
:
: This study adhered to the principles outlined in the Declaration of Helsinki and was carried out with the approval of the Institutional Review Board at Inova Fairfax Hospital (IRB U23-03-5032). The requirement for informed consent was waived by the Institutional Review Board due to the retrospective nature of the study and the use of anonymized clinical data.
: Not applicable.
: SDN is a consultant and is on the speaker’s bureau for both Boehringer-Ingelheim and United Therapeutics. He has also received research funding from both Companies. He is also on the steering committee for IPF studies by Tvardi and Avalyn Pharma. CSK is a speaker for and has participated in advisory boards for United Therapeutics as well as Merck and Jannsen. CAT has participated in advisory boards for Jannsen. VK is a speaker for and has participated in advisory boards for Jannsen. None of the other investigators have any conflicts of interest with regards to this study.
